Brokers Set Expectations for DYAI FY2024 Earnings

Dyadic International, Inc. (NASDAQ:DYAI) – Equities research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Dyadic International in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino expects that the biotechnology company will post earnings of ($0.15) per share for the year. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Dyadic International’s Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($0.06) EPS.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter in the previous year, the company posted ($0.06) EPS.

Dyadic International Stock Up 3.5 %

Shares of Dyadic International stock opened at $1.17 on Monday. The business has a fifty day simple moving average of $1.12 and a 200 day simple moving average of $1.41. The stock has a market cap of $34.62 million, a PE ratio of -5.09 and a beta of 0.72. The company has a quick ratio of 5.39, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. raised its position in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 as of its most recent filing with the SEC. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.